LabGenomics Turns to Operating Profit in Q3... Performance Improves Through Management Efficiency and Diversification of Sales Channels

LabGenomics announced on the 17th that it successfully returned to an operating profit on a standalone basis in the third quarter of this year, putting an end to the streak of losses that had continued since last year.

The company explained that, since the beginning of this year, it has prioritized improving profitability by implementing management efficiency measures, restructuring its business portfolio, and diversifying its sales channels. These efforts have led to tangible results, accelerating its organizational transformation.

Chief Executive Officer Ryu Jaehak, who joined the company earlier this year and was promoted from Executive Vice President to CEO at an extraordinary general shareholders’ meeting in June, has a background at a major domestic pharmaceutical company. From the outset, CEO Ryu has driven rapid improvements in the company’s profit structure and business fundamentals by leveraging his experience in advanced management systems and sales strategies from the pharmaceutical sector, focusing on controlling unnecessary company-wide costs and enhancing production efficiency.

The company is concentrating on improving productivity in each division by streamlining its specimen testing sales organization, benchmarking the sales processes of the pharmaceutical industry, and strengthening a performance-based HR system. In addition, it has established a new marketing team and recruited Executive Director Kim Byungki, who also comes from the pharmaceutical sector, to further diversify sales channels such as general hospitals and enhance business competitiveness in the market.

Businesses that failed to deliver growth or profitability relative to the resources invested have been decisively discontinued. LabGenomics is now focusing on NGS-based businesses and strengthening strategic alliances, aiming to achieve both sales growth and improved profitability, while also establishing a sustainable business structure.

In particular, the company has solidified its market leadership in the NIPT (non-invasive prenatal testing) segment through collaboration with major domestic biopharma companies, and sales in this area are rapidly increasing. Additionally, LabGenomics is expanding its portfolio of chronic disease tests, including cancer and Alzheimer’s disease, in response to an aging society, and continues to pursue strategic partnerships with leading domestic pharmaceutical companies.

According to the Financial Supervisory Service’s electronic disclosure system, standalone sales in the third quarter of this year amounted to 10.1 billion won (up 11% year-on-year), and operating profit was 200 million won (a return to profitability). During the same period, cost of goods sold and selling, general and administrative expenses decreased by 4% and 23%, respectively, resulting in a significant improvement in profitability.

A LabGenomics official stated, "Although an operating loss continues on a consolidated basis, quarterly operating losses from the U.S. business are also shrinking, so we expect to see growth going forward."

This content was produced with the assistance of AI translation services.